Clinical trial · no report yet · Phase 3
RELATIVITY-098
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
- NCT05002569 ↗
- Terminated
- Bristol-Myers Squibb
- 25 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 9 | |
| Podcasts | 9 | |
| X threads | 7 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Melanoma
- Interventions
- Nivolumab; Nivolumab + Relatlimab Fixed Dose Combination
- Arms
- Arm A: Nivolumab Plus Relatlimab · Experimental
- Arm B: Nivolumab · Experimental
- Enrollment
- 1,093
- Primary outcomes
- Recurrence Free Survival (RFS)
- Sponsor
- Bristol-Myers Squibb
- Start
- Oct 19, 2021
- Primary completion
- Dec 16, 2024
- Results posted
- Yes
- Registry record
- NCT05002569 · updated Jan 8, 2026
Publications
linked from the registry- Long GV, Garnett-Benson C, Dolfi S, Ascierto PA, Guo J, Tarhini AA, Chandra S, Munoz-Couselo E, Del Vecchio M, de Melo AC, Callahan M, Gogas H, Dummer R, Schadendorf D, Koelblinger P, Quereux G, Thomas I, Yu JX, Fisher A, Wang B, Djidel P, Chouzy A, Semaan M, Chen B, Cheong AMY, Tawbi HA. Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgery. Future Oncol. 2026 Sep 22:1-10. doi: 10.1080/14796694.2026.2721180. Online ahead of print. PubMed 42770835
- Long GV, Garnett-Benson C, Dolfi S, Ascierto PA, Guo J, Tarhini AA, Chandra S, Munoz-Couselo E, Del Vecchio M, de Melo AC, Callahan M, Gogas H, Dummer R, Schadendorf D, Koelblinger P, Quereux G, Thomas I, Yu JX, Fisher A, Wang B, Djidel P, Chouzy A, Semaan M, Chen B, Cheong AMY, Tawbi HA. Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial. Nat Med. 2025 Dec;31(12):4301-4309. doi: 10.1038/s41591-025-04032-8. Epub 2025 Oct 18. PubMed 41109920